Covalon Technologies Ltd. (COV.V)
CAD 2.35
(3.07%)
CAD 2.35
(3.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 26.59 Million CAD | 46.56% |
| 2022 | 18.14 Million CAD | -7.23% |
| 2021 | 19.56 Million CAD | -24.18% |
| 2020 | 25.8 Million CAD | -24.13% |
| 2019 | 34 Million CAD | 27.25% |
| 2018 | 26.72 Million CAD | -2.15% |
| 2017 | 27.3 Million CAD | 306.94% |
| 2016 | 6.71 Million CAD | -11.57% |
| 2015 | 7.58 Million CAD | -16.25% |
| 2014 | 9.06 Million CAD | 119.18% |
| 2013 | 4.13 Million CAD | 8.98% |
| 2012 | 3.79 Million CAD | 46.58% |
| 2011 | 2.58 Million CAD | -19.9% |
| 2010 | 3.23 Million CAD | 41.37% |
| 2009 | 2.28 Million CAD | -7.58% |
| 2008 | 2.47 Million CAD | 92.35% |
| 2007 | 1.28 Million CAD | 36.95% |
| 2006 | 938.8 Thousand CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.66 Million CAD | -32.37% |
| 2024 Q2 | 8.41 Million CAD | 80.43% |
| 2024 Q3 | 9.22 Million CAD | 9.64% |
| 2023 Q1 | 6.18 Million CAD | 14.75% |
| 2023 Q4 | 6.89 Million CAD | 9.97% |
| 2023 Q2 | 7.24 Million CAD | 17.12% |
| 2023 FY | 26.59 Million CAD | 46.56% |
| 2023 Q3 | 6.27 Million CAD | -13.45% |
| 2022 Q4 | 5.39 Million CAD | 19.09% |
| 2022 Q3 | 4.52 Million CAD | 37.41% |
| 2022 FY | 18.14 Million CAD | -7.23% |
| 2022 Q1 | 4.93 Million CAD | 348.82% |
| 2022 Q2 | 3.29 Million CAD | -33.27% |
| 2021 Q4 | -1.98 Million CAD | -122.5% |
| 2021 Q1 | 5.98 Million CAD | 1.16% |
| 2021 FY | 19.56 Million CAD | -24.18% |
| 2021 Q2 | 6.74 Million CAD | 12.57% |
| 2021 Q3 | 8.81 Million CAD | 30.77% |
| 2020 Q4 | 5.91 Million CAD | -11.3% |
| 2020 Q3 | 6.67 Million CAD | 26.91% |
| 2020 FY | 25.8 Million CAD | -24.13% |
| 2020 Q2 | 5.25 Million CAD | -33.84% |
| 2020 Q1 | 7.94 Million CAD | 20.86% |
| 2019 Q2 | 13.31 Million CAD | 83.33% |
| 2019 FY | 34 Million CAD | 27.25% |
| 2019 Q1 | 7.26 Million CAD | 9.07% |
| 2019 Q3 | 6.85 Million CAD | -48.51% |
| 2019 Q4 | 6.57 Million CAD | -4.05% |
| 2018 Q2 | 5.72 Million CAD | -10.58% |
| 2018 Q3 | 7.93 Million CAD | 38.52% |
| 2018 FY | 26.72 Million CAD | -2.15% |
| 2018 Q1 | 6.4 Million CAD | -34.89% |
| 2018 Q4 | 6.65 Million CAD | -16.08% |
| 2017 Q4 | 9.83 Million CAD | 66.69% |
| 2017 FY | 27.3 Million CAD | 306.94% |
| 2017 Q1 | 5.6 Million CAD | 542.77% |
| 2017 Q2 | 6 Million CAD | 7.07% |
| 2017 Q3 | 5.9 Million CAD | -1.73% |
| 2016 Q1 | 2.44 Million CAD | 16.36% |
| 2016 Q4 | 872.62 Thousand CAD | -66.44% |
| 2016 Q3 | 2.6 Million CAD | 225.92% |
| 2016 Q2 | 797.74 Thousand CAD | -67.31% |
| 2016 FY | 6.71 Million CAD | -11.57% |
| 2015 FY | 7.58 Million CAD | -16.25% |
| 2015 Q3 | 1.97 Million CAD | -9.45% |
| 2015 Q4 | 2.09 Million CAD | 6.23% |
| 2015 Q2 | 2.18 Million CAD | 63.11% |
| 2015 Q1 | 1.33 Million CAD | 10.82% |
| 2014 Q3 | 1.29 Million CAD | -36.75% |
| 2014 Q4 | 1.2 Million CAD | -6.6% |
| 2014 FY | 9.06 Million CAD | 119.18% |
| 2014 Q1 | 4.52 Million CAD | 190.88% |
| 2014 Q2 | 2.04 Million CAD | -54.85% |
| 2013 Q2 | 529.85 Thousand CAD | -7.37% |
| 2013 Q3 | 1.47 Million CAD | 178.88% |
| 2013 FY | 4.13 Million CAD | 8.98% |
| 2013 Q4 | 1.55 Million CAD | 5.21% |
| 2013 Q1 | 572 Thousand CAD | -38.87% |
| 2012 Q3 | 1.07 Million CAD | -1.05% |
| 2012 Q4 | 935.68 Thousand CAD | -13.25% |
| 2012 FY | 3.79 Million CAD | 46.58% |
| 2012 Q1 | 689.16 Thousand CAD | 20.39% |
| 2012 Q2 | 1.09 Million CAD | 58.17% |
| 2011 Q2 | 1.01 Million CAD | 52.99% |
| 2011 Q1 | 661.11 Thousand CAD | 9.19% |
| 2011 FY | 2.58 Million CAD | -19.9% |
| 2011 Q4 | 572.42 Thousand CAD | 66.86% |
| 2011 Q3 | 343.04 Thousand CAD | -66.08% |
| 2010 Q1 | 794.67 Thousand CAD | 29.31% |
| 2010 Q4 | 605.47 Thousand CAD | -39.6% |
| 2010 Q3 | 1 Million CAD | 20.99% |
| 2010 Q2 | 828.52 Thousand CAD | 4.26% |
| 2010 FY | 3.23 Million CAD | 41.37% |
| 2009 FY | 2.28 Million CAD | -7.58% |
| 2009 Q1 | 358.67 Thousand CAD | -64.05% |
| 2009 Q3 | 427.37 Thousand CAD | -45.31% |
| 2009 Q2 | 781.43 Thousand CAD | 117.87% |
| 2009 Q4 | 614.54 Thousand CAD | 43.8% |
| 2008 Q1 | 607.33 Thousand CAD | 56.9% |
| 2008 FY | 2.47 Million CAD | 92.35% |
| 2008 Q3 | 337.26 Thousand CAD | 9.35% |
| 2008 Q2 | 308.41 Thousand CAD | -49.22% |
| 2008 Q4 | 997.73 Thousand CAD | 195.83% |
| 2007 Q1 | 337.76 Thousand CAD | 3.5% |
| 2007 Q3 | 203.42 Thousand CAD | -43.08% |
| 2007 Q4 | 387.08 Thousand CAD | 90.29% |
| 2007 Q2 | 357.4 Thousand CAD | 5.81% |
| 2007 FY | 1.28 Million CAD | 36.95% |
| 2006 Q3 | 351.22 Thousand CAD | 164.0% |
| 2006 FY | 938.8 Thousand CAD | 0.0% |
| 2006 Q4 | 326.34 Thousand CAD | -7.08% |
| 2006 Q1 | 137.09 Thousand CAD | 0.0% |
| 2006 Q2 | 133.04 Thousand CAD | -2.96% |
| 2005 Q4 | - CAD | -100.0% |
| 2005 Q2 | 7334.00 CAD | 225.96% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q1 | 2250.00 CAD | 0.0% |
| 2005 Q3 | 41.31 Thousand CAD | 463.31% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Arch Biopartners Inc. | 1.98 Million CAD | -1240.729% |
| Hemostemix Inc. | - CAD | -Infinity% |
| Universal Ibogaine Inc. | 1.07 Million CAD | -2383.675% |
| Kane Biotech Inc. | 148.98 Thousand CAD | -17751.581% |
| MedMira Inc. | 432.52 Thousand CAD | -6048.787% |
| Marvel Biosciences Corp. | - CAD | -Infinity% |
| NervGen Pharma Corp. | - CAD | -Infinity% |
| XORTX Therapeutics Inc. | - CAD | -Infinity% |